Genmab A/S Sponsored ADR (GMAB)

Last Price:  

Company Description

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $804.57M
Net Income (Most Recent Fiscal Year) $324.68M
PE Ratio (Current Year Earnings Estimate) 33.58
PE Ratio (Trailing 12 Months) 18.77
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 26.97
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 10.71
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) 65.75
Pre-Tax Margin (Trailing 12 Months) 53.28%
Net Margin (Trailing 12 Months) 41.69%
Return on Equity (Trailing 12 Months) 19.19%
Return on Assets (Trailing 12 Months) 17.91%
Current Ratio (Most Recent Fiscal Quarter) 19.04
Quick Ratio (Most Recent Fiscal Quarter) 19.04
Debt to Common Equity (Most Recent Fiscal Quarter) 0.01
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $3.24
Earnings per Share (Most Recent Fiscal Quarter) $0.06
Earnings per Share (Most Recent Fiscal Year) $0.51
Diluted Earnings per Share (Trailing 12 Months) $1.86
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 652.80M
Free Float --
Market Capitalization $22.80B
Average Volume (Last 20 Days) 0.79M
Beta (Past 60 Months) --
Percentage Held By Insiders (Latest Annual Proxy Report) --
Percentage Held By Institutions (Latest 13F Reports) 4.37%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%